Population pharmacokinetic model of fluvoxamine in rats: Utility for application in animal behavioral studies

European Journal of Pharmaceutical Sciences

Volumn 30, Issue 1, 2007, Pages 45-55

  Geldof, Marian ^a   Freijer, Jan ^b   van Beijsterveldt, Ludy ^c   Timmerman, Philip ^c   Ahnaou, Abdellah ^c   Drinkenburg, Wilhelmus H I M ^c   Danhof, Meindert ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b LAP and P Consultants BV   (Netherlands)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Co variate analysis; Non linear mixed effects modeling; Rapid eye movement sleep; Selective serotonin reuptake inhibitor; Sparse sampling

Indexed keywords

FLUVOXAMINE MALEATE;

ANIMAL BEHAVIOR; ARTICLE; BODY WEIGHT; BOOTSTRAPPING; CORRELATION ANALYSIS; COVARIANCE; DRUG CLEARANCE; NONHUMAN; PREDICTIVE VALIDITY; PRIORITY JOURNAL; REM SLEEP;

ANIMALS; BEHAVIOR, ANIMAL; FLUVOXAMINE; INFUSIONS, INTRAVENOUS; MALE; MODELS, BIOLOGICAL; RATS; RATS, WISTAR; SEROTONIN UPTAKE INHIBITORS; SLEEP, REM;

EID: 33845430720     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2006.10.001     Document Type: Article

References (25)

1. Bel N., and Artigas F. Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: an in vivo microdialysis study. Eur. J. Pharmacol. 229 (1992) 101-103
2. Bonate P.L., Floret S., and Bentzen C. Population pharmacokinetics of APOMINE: a meta-analysis in cancer patients and healthy males. Br. J. Clin. Pharmacol. 58 (2004) 142-155
3. Coppen A. The biochemistry of affective disorders. Br. J. Psychiatry 113 (1967) 1237-1264
4. Cox E.H., Veyrat-Follet C., Beal S.L., Fuseau E., Kenkare S., and Sheiner L.B. A population pharmacokinetic-pharmacodynamic analysis of repeated measures time-to-event pharmacodynamic responses: the antiemetic effect of ondansetron. J. Pharmacokinet. Biopharm. 27 (1999) 625-644
5. Della Paschoa O.E., Kruk M.R., and Danhof M. Phamacokinetic-pharmacodynamic modelling of behavioural responses. Neurosci. Biobehav. Rev. 23 (1998) 229-236
6. DeVane C.L., and Gill H.S. Clinical pharmacokinetics of fluvoxamine: applications to dosage regimen design. J. Clin. Psychiatry 58 Suppl. 5 (1997) 7-14
7. Fuller R.W. Uptake inhibitors increase extracellular serotonin concentration measured by brain microdialysis. Life Sci. 55 (1994) 163-167
8. Gieschke R., and Steimer J.L. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development. Eur. J. Drug Metab. Pharmacokinet. 25 (2000) 49-58
9. Hashimoto Y., and Sheiner L.B. Designs for population pharmacodynamics: value of pharmacokinetic data and population analysis. J. Pharmacokinet. Biopharm. 19 (1991) 333-353
10. Iwi G., Millard R.K., Palmer A.M., Preece A.W., and Saunders M. Bootstrap resampling: a powerful method of assessing confidence intervals for doses from experimental data. Phys. Med. Biol. 44 (1999) N55-N62
11. Jonker D.M., Vermeij D.A., Edelbroek P.M., Voskuyl R.A., Piotrovsky V.K., and Danhof M. Pharmacodynamic analysis of the interaction between tiagabine and midazolam with an allosteric model that incorporates signal transduction. Epilepsia 44 (2003) 329-338
12. Kelliher P., Kelly J.P., Leonard B.E., and Sanchez C. Effects of acute and chronic administration of selective monoamine re-uptake inhibitors in the rat forced swim test. Psychoneuroendocrinology 28 (2003) 332-347
13. Owens M.J., and Nemeroff C.B. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin. Chem. 40 (1994) 288-295
14. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1982), Academic Press
15. Preskorn S.H. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin. Pharmacokinet. 32 Suppl. 1 (1997) 1-21
16. Schoemaker R.C., and Cohen A.F. Estimating impossible curves using NONMEM. Br. J. Clin. Pharmacol. 42 (1996) 283-290
17. Sheiner L.B., and Ludden T.M. Population pharmacokinetics/dynamics. Annu. Rev. Pharmacol. Toxicol. 32 (1992) 185-209
18. Takamori K., Yoshida S., and Okuyama S. Availability of learned helplessness test as a model of depression compared to a forced swimming test in rats. Pharmacology 63 (2001) 147-153
19. Teste J.F., Pelsy-Johann I., Decelle T., and Boulu R.G. Anti-immobility activity of different antidepressant drugs using the tail suspension test in normal or reserpinized mice. Fundam. Clin. Pharmacol. 7 (1993) 219-226
20. Vis P., Della P.O., Kruk M., Martin D., Mocaer E., Danhof M., and Jochemsen R. Population pharmacokinetic-pharmacodynamic modelling of S 15535, a 5-HT(1A) receptor agonist, using a behavioural model in rats. Eur. J. Pharmacol. 414 (2001) 233-243
21. Vozeh S., Steimer J.L., Rowland M., Morselli P., Mentre F., Balant L.P., and Aarons L. The use of population pharmacokinetics in drug development. Clin. Pharmacokinet. 30 (1996) 81-93
22. Wilson S.J., Bailey J.E., Alford C., and Nutt D.J. Sleep and daytime sleepiness the next day following single night-time dose of fluvoxamine, dothiepin and placebo in normal volunteers. J. Psychopharmacol. 14 (2000) 378-386
23. Wilson S.J., Bell C., Coupland N.J., and Nutt D.J. Sleep changes during long-term treatment of depression with fluvoxamine-a home-based study. Psychopharmacology (Berlin) 149 (2000) 360-365
24. Yano Y., Beal S.L., and Sheiner L.B. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J. Pharmacokinet. Pharmacodyn. 28 (2001) 171-192
25. Yuh L., Beal S., Davidian M., Harrison F., Hester A., Kowalski K., Vonesh E., and Wolfinger R. Population pharmacokinetic/pharmacodynamic methodology and applications: a bibliography. Biometrics 50 (1994) 566-575